

Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care

NCT05287022

Status RECRUITING
Sponsor Arkansas Children's Hospital Research Institute
Enrollment 150 participants

Key Eligibility Criteria

Inclusion (13)

- Individuals who are diagnosed with Primary Ciliary Dyskinesia OR
- Individuals with abnormal PCD diagnostics (abnormal ciliary biopsy or PCD genetics) OR
- Individuals with unexplained bronchiectasis OR
- Individuals undergoing PCD diagnostic testing (ciliary biopsy, PCD genetic testing) or concern based on clinical symptoms (at least two of the following):
- Neonatal respiratory distress
- ... and 8 more (see full listing online)

Exclusion (6)

- Individuals who are unable to understand the requirements of the study.
- Individuals (or guardians) who are unwilling to provide consent.
- Individuals who are unable to complete the testing
- Recent history of sinus surgery (within four weeks) or bloody nose (within one week) of testing (they can be included at a later date)
- Patients who are currently being treated (within one week) with antibiotics for sinusitis or respiratory symptoms (they can be included at a later date)
- ... and 1 more (see full listing online)

Locations (1 total)

Arkansas Children's Hospital, Little Rock, Arkansas, United States